Pfizer Inc. (NYSE:PFE) Shares Acquired by Roberts Glore & Co. Inc. IL

Roberts Glore & Co. Inc. IL increased its position in Pfizer Inc. (NYSE:PFE) by 4.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,993 shares of the biopharmaceutical company’s stock after buying an additional 1,649 shares during the period. Roberts Glore & Co. Inc. IL’s holdings in Pfizer were worth $1,088,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Coordinated Financial Services Inc. acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $207,000. Axis Wealth Partners LLC acquired a new position in Pfizer during the fourth quarter worth approximately $290,000. Blake Schutter Theil Wealth Advisors LLC increased its position in Pfizer by 33.2% during the fourth quarter. Blake Schutter Theil Wealth Advisors LLC now owns 13,889 shares of the biopharmaceutical company’s stock worth $368,000 after purchasing an additional 3,461 shares during the last quarter. Naviter Wealth LLC increased its position in Pfizer by 18.6% during the fourth quarter. Naviter Wealth LLC now owns 60,033 shares of the biopharmaceutical company’s stock worth $1,593,000 after purchasing an additional 9,408 shares during the last quarter. Finally, Marble Harbor Investment Counsel LLC increased its position in Pfizer by 5.4% during the fourth quarter. Marble Harbor Investment Counsel LLC now owns 356,809 shares of the biopharmaceutical company’s stock worth $9,466,000 after purchasing an additional 18,254 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Citigroup dropped their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wolfe Research assumed coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

Shares of PFE stock opened at $26.71 on Friday. The company has a market capitalization of $151.35 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The firm has a fifty day simple moving average of $26.30 and a 200-day simple moving average of $27.24. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were paid a $0.43 dividend. The ex-dividend date was Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.44%. Pfizer’s dividend payout ratio is 121.99%.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.